Vanda Pharmaceuticals Inc. splits its revenue into 4 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Fanapt at $38.8 million, 56% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
229
|
70
|
51
|
52
|
57
|
56
|
53
|
50
|
53
|
| Fanapt |
—
|
39
+24.1%
share 55.5%
|
36
+22.9%
share 71.2%
|
30
+25.5%
share 57.2%
|
33
share 58.1%
|
31
share 55.5%
|
29
share 55.7%
|
24
share 47.1%
|
—
|
| Hetlioz |
—
|
22
+20.6%
share 31.1%
|
6
-65.6%
share 11.0%
|
16
-23.6%
share 30.8%
|
16
-18.2%
share 28.6%
|
18
share 32.0%
|
16
share 30.8%
|
21
share 41.7%
|
20
share 37.7%
|
| PONVORY |
—
|
8
+10.1%
share 11.1%
|
8
+11.7%
share 15.7%
|
6
+10.4%
share 12.0%
|
8
+17.2%
share 13.3%
|
7
share 12.5%
|
7
share 13.5%
|
6
share 11.2%
|
6
share 12.2%
|
| NEREUS |
—
|
2
share 2.3%
|
1
share 2.0%
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VNDA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Washington, DC
- SEC filer status
- Accelerated filer
- SEC CIK
- 1347178
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.